{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:55:08Z","timestamp":1787320508156,"version":"build-2736575974"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment landscape for hemophilia has evolved rapidly over the past decade, with the approval of several therapies with novel mechanisms of action. Extended half-life factor concentrates and nonfactor therapies, including factor VIII mimetics and rebalancing agents, have reduced treatment burden while also improving bleed protection. Although these new therapies provide an unprecedented ability to personalize treatment and to meet changing needs across the life span for each individual, the complexity of these treatment considerations has made clinical decision-making and selection of the optimal treatment challenging for those living with hemophilia and their clinicians.<\/jats:p>","DOI":"10.1182\/hematology.2025000764","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:39Z","timestamp":1764943839000},"page":"668-673","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["New therapies in hemophilia: extend the half-life, mimic, or rebalance?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Mark T.","family":"Reding","sequence":"first","affiliation":[{"name":"University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"3","key":"2025120616353290300_hem2025000764C1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025120616353290300_hem2025000764C2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2025120616353290300_hem2025000764C3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2025120616353290300_hem2025000764C4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2025120616353290300_hem2025000764C5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025120616353290300_hem2025000764C6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2025120616353290300_hem2025000764C7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2025120616353290300_hem2025000764C8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"26","key":"2025120616353290300_hem2025000764C9","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2025120616353290300_hem2025000764C10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025120616353290300_hem2025000764C11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","article-title":"Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A","volume":"128","author":"Mahlangu","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2025120616353290300_hem2025000764C12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ejh.14114","article-title":"Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A","volume":"112","author":"Reding","year":"2024","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025120616353290300_hem2025000764C13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616353290300_hem2025000764C14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616353290300_hem2025000764C15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"16","key":"2025120616353290300_hem2025000764C16","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025120616353290300_hem2025000764C17","doi-asserted-by":"crossref","first-page":"102364","DOI":"10.1016\/j.rpth.2024.102364","article-title":"Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies","volume":"8","author":"Mahlangu","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"issue":"1","key":"2025120616353290300_hem2025000764C18","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.rpth.2025.102696","article-title":"Contemporary approaches to treat people with hemophilia: what's new and what's not?","volume":"9","author":"Valentino","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"2025120616353290300_hem2025000764C19","article-title":"Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: phase 3, open-label, randomized, controlled, FRONTIER2 study","author":"Mancuso"},{"issue":"2","key":"2025120616353290300_hem2025000764C20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2025120616353290300_hem2025000764C21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-024-02130-4","article-title":"Marstacimab: first approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"issue":"11","key":"2025120616353290300_hem2025000764C22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2025120616353290300_hem2025000764C23","article-title":"Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors","author":"Matino"},{"issue":"4","key":"2025120616353290300_hem2025000764C24","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"issue":"2","key":"2025120616353290300_hem2025000764C25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ijlh.14406","article-title":"Thrombin generation assay to support hematologists in the era of new hemophilia therapies","volume":"47","author":"Josset","year":"2025","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2025120616353290300_hem2025000764C26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0044-1796651","article-title":"Non-factor therapies for hemophilia: achievements and perspectives","volume":"51","author":"Jim\u00e9nez-Yuste","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2025120616353290300_hem2025000764C27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/hae.15100","article-title":"Development of the World Federation of Hemophilia shared decision-making tool","volume":"30","author":"Coffin","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"2025120616353290300_hem2025000764C28","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.rpth.2025.102726","article-title":"O'Mahony B. Hemophilia treatments and the paradox of choice","volume":"9","author":"Makris","year":"2025","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/668\/2470432\/668reding.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/668\/2470432\/668reding.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:43Z","timestamp":1765056943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/668\/556915\/New-therapies-in-hemophilia-extend-the-half-life"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000764","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}